

Financial Tear Sheet

Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$17.40
Change (%)	▲ 0.86 (5.20%)
Volume	38,760
52 Week Low	\$13.13
Market Cap	\$337,502,928
Rolling EPS	-5.95
PE Ratio	0
Shares Outstanding	19,396,720
Data as of 11/22/17 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

News & Events

Date	Title
11/09/17	Merus to Present at the Jefferies London Healthcare Conference
10/10/17	Merus to Participate in the BIO Investor Forum

There are currently no events scheduled.

09/20/17 Merus' Intellectual Property Portfolio Expands with Two New Patents For its Biclomics® Technology

SEC Filings

Filing Date	Form
09/27/17	SC 13D/A
09/22/17	6-K
09/15/17	SC 13G/A
07/20/17	SC 13D/A

Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Mark Iwicki	Chairman, Non-Executive Director
Wolfgang Berthold, Ph.D.	Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
Lionel Carnot	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director

Primary IR Contact

Kimberly Minarovich
Argot Partners
Phone: 1 212-600-1902
E-mail: kimberly@argotpartners.com

Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO